Antibacterial agent, Anti-inflammatory agent and topical skin preparation

Mucuna bean-based formulations address the limitations of existing anti-allergic agents by offering effective cytokine suppression and antibacterial properties, reducing side effects and costs, and enhancing skin preparations for allergic dermatitis.

JP2024160441AInactive Publication Date: 2024-11-14SOUSHIN CORP +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2023075418
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-01
Publication Date
2024-11-14
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing anti-allergic agents, such as steroid preparations and antihistamines, pose significant side effects and are not effective in suppressing cytokines that cause inflammation in allergic dermatitis, and natural alternatives like mastic and mucuna beans have production and transportation limitations.

Method used

Utilizing mucuna beans as an active ingredient in antibacterial and anti-inflammatory agents, formulated as powders or extracts within specific concentration ranges, optionally combined with mastic-derived components and other additives, to create immunosuppressive and anti-inflammatory skin preparations.

Benefits of technology

The formulation effectively suppresses cytokines related to allergic dermatitis and Staphylococcus aureus, reducing side effects and manufacturing costs while providing antibacterial and anti-inflammatory benefits.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024160441000001_ABST
    Figure 2024160441000001_ABST
Patent Text Reader

Abstract

To provide an antibacterial agent, an anti-inflammatory agent and a topical skin preparation each comprising Mucuna pruriens var. utilis as an active ingredient.SOLUTION: The present invention provides an antibacterial agent, an anti-inflammatory agent and a topical skin preparation each comprising Mucuna pruriens var. utilis as an active ingredient.SELECTED DRAWING: Figure 2
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an antibacterial agent, an anti-inflammatory agent, and an external skin preparation which contain Mucuna pruriens (Mucuna pruriens or velvet bean) as an active ingredient. [Background technology]

[0002] Allergies or allergic reactions are excessive immune responses to specific antigens. The causes of allergies have not been clarified, but it is thought that they may be due to the living environment, excessive exposure to antigens, genetics, etc. Antigens that cause allergies are specifically called allergens. Allergens can be a wide variety of things, including those derived from living organisms or plants such as house dust, dog or cat hair, mites, mold, pollen, etc., and those derived from foods such as buckwheat, rice, wheat, yeast, gelatin, dairy products, and chicken eggs. In addition, some ingredients in medicines can also be allergens.

[0003] Here, the mechanisms by which immune responses to allergens occur include excessive responses of immunoglobulin antibodies such as IgE, IgG, or IgM to allergens, excessive responses of sensitized T cells to allergens, and excessive responses of helper T cells or their subspecies (e.g., Th1 and Th2 cells) and / or neutrophils, eosinophils, macrophages, and cytokines (mainly interleukin (IL)) to allergens.

[0004] Allergic reactions then lead to the development of so-called allergic diseases, such as atopic dermatitis, allergic rhinitis (hay fever), allergic conjunctivitis, allergic gastroenteritis, bronchial asthma, childhood asthma, food allergies, drug allergies, urticaria, etc. Although the above-mentioned allergic diseases mainly occur in humans, other mammals (e.g., dogs and cats) also develop diseases such as dermatitis and conjunctivitis, just like humans.

[0005] Meanwhile, there are antagonists, inhibitors, suppressors, or releasers for treating allergic diseases, that is, for receptors (e.g., leukotriene LT receptors and histamine H1 receptors) and mediators (histamine and cytokines) themselves that control excessive immune reactions. In the above-mentioned antagonism, inhibition, suppression, or release of immune reactions, they are roughly classified into steroid-based preparations that contain steroid compounds as active ingredients, and non-steroidal preparations that are not based on steroids, such as first- or second-generation antihistamine preparations and chemical mediator releasers.

[0006] In general, steroid-based preparations mainly play a role in suppressing immune responses and the functions of receptors and mediators that control immune responses. Furthermore, steroid-based preparations are not only used as antiallergic agents as immunosuppressants, but are also used as anti-inflammatory agents, vasoconstrictors, and cell proliferation inhibitors, and are available in various dosage forms such as oral medications, topical skin preparations (liniments), eye drops, and infusions. However, steroid-based preparations have the drawback that if they are used incorrectly in a state of mild or minor injury or near asymptomatic illness, they can have an inhibitory effect on factors that are not directly related to allergies or diseases (e.g., hormones such as insulin), which can lead to a high possibility of side effects. In addition, non-steroidal antiallergic agents, such as antihistamines, also have the drawback of causing side effects similar to non-steroidal drugs if the active ingredient is the majority. [Prior art documents] [Patent documents]

[0007] [Patent Document 1] JP 2018-83764 A [Patent Document 2] International Publication No. 2021 / 235512 [Patent Document 3] JP 2008-81478 A [Non-patent literature]

[0008] [Non-Patent Document 1] Konishi, Fumiko, “Research on the Cooking Properties, Functionality, and Preference of Various Foods,” Journal of the Japan Society of Home Economics, Vol. 73, No. 6, pp. 295-205 (2022). Summary of the Invention [Problem to be solved by the invention]

[0009] Here, in order to eliminate concerns about side effects of non-steroidal antiallergic agents such as steroidal preparations and / or antihistamines, immunomodulatory compositions derived from natural products have been disclosed in recent years, for example, in JP 2018-83764 A (Patent Document 1). The composition according to Patent Document 1 is a composition that uses sea thistle of the genus Cirsium of the Asteraceae family or an extract thereof as an active ingredient to express an immunosuppressive function. The composition is then mixed with food or the like for use. However, Patent Document 1 describes that sirsimarin and / or sirsimaritin contained in sea thistle extract are the main components related to immunomodulation, and that the whole plant part of sea thistle, such as leaves and stems, can be dried and used, but in the end, the dried product is also extracted with hot water and used. In order to further improve the accuracy as an immunomodulatory composition, the extract must be further purified by chromatography or the like to isolate sirsimarin and / or sirsimaritin. The extract in this case must also be extracted using an organic solvent, not hot water, so depending on the solvent used, the distillation of the solvent is likely to be a burden.

[0010] As mentioned above, mastic (mastiha) is known as a material that can be isolated and purified without using organic solvents. Mastic (mastiha) is a plant of the genus Pistacia (Pistacia lentiscus) of the Anacardiaceae family, and is only produced on the Greek island of Chios. Mastic is known to have bactericidal and antimicrobial effects, such as killing Helicobacter pylori and Clostridium botulinum, which cause gastrointestinal diseases, killing periodontal disease bacteria in both humans and non-human animals (e.g., dogs and cats), lowering blood pressure, and lowering blood sugar levels, as well as lowering cholesterol, immunostimulating effects, promoting bile secretion, preventing tongue coating that turns the tongue white, relieving pain from gout and rheumatism, killing wounds, promoting wound healing, and more. In recent years, it has also become known to have antibacterial effects against oral bacteria or fungi, such as caries bacteria, periodontal disease bacteria, and opportunistic infection bacteria. Generally, mastic is used in three forms: "mastic sap" containing masticadienoic acid, isomasticadienoic acid, triterpenes, aldehydes, alcohols, poly-β-myrcene, etc. as main components, "mastic resin" which is mastic sap that has been naturally dried and solidified, and "mastic essential oil" which is mastic sap or mastic resin that has been steam distilled or dry distilled to extract volatile components (mainly terpenes) into essential oil. When separating mastic into each of the forms mentioned above, extraction and isolation can be performed by simple and safe methods such as natural drying and steam distillation without extraction and separation using organic solvents.

[0011] The applicants of the present application have disclosed antibacterial agents, anti-inflammatory agents, skin topical preparations, cosmetics, and transdermal topical preparations containing mastic-derived components in International Publication No. 2021 / 235512 (Patent Document 2). Here, the invention described in Patent Document 2 targets Th2-type allergies including atopic dermatitis and finds that mastic-derived components have inhibitory effects on cytokines (IL-4, IL-9, IL-13), IL-1β, periostin, and TSLP (thymic stromal lymphopoietin). However, in Patent Document 2, as mentioned above, mastic itself is only produced on the Greek island of Chios, and therefore is not suitable for mass production due to the associated transportation costs.

[0012] Meanwhile, Mucuna bean (also known as velvet bean or medicament; hereafter in this specification, we will refer to it as "Mucuna bean") has been attracting attention in recent years as a natural material that contains ingredients similar to the above-mentioned mastic, which are expected to have multifunctional effects, such as immunosuppressive effects.

[0013] Mucuna beans contain L-DOPA (3,4-dihydroxy-L-phenylalanine), a dopamine precursor, and are expected to be an alternative to L-DOPA preparations, which are a specific medicine for Parkinson's disease, and are also known to have an inhibitory effect on β-amyloid and tau proteins, which are one of the main causes of Alzheimer's dementia (see Non-Patent Document 1). Furthermore, the inclusion of L-DOPA is expected to improve psychological problems such as depression and stress relief. In addition to L-DOPA, Mucuna beans contain L-α-amino acids and polyphenols, both essential and non-essential, and are therefore expected to reduce fatigue, lower blood sugar levels, lower blood pressure, and have antioxidant effects. An invention in which an extract extracted from Mucuna beans is applied to food and drinking water is disclosed, for example, in JP 2008-81478 A (Patent Document 3). In the invention described in Patent Document 3, the polyphenol-polysaccharide complex contained in the extract is used as an activating substance, and it has been discovered that it has anti-cancer and cancer prevention effects, including immune function enhancing activity and the ability to induce apoptosis in cancer cells.

[0014] However, although Patent Document 3 is aware of the enhancing effect of the immunostimulatory effect of activating cytokines such as interleukin 6 (IL-6) and tumor necrosis factor (TNF-α) produced by dendritic cells, it does not disclose or suggest anything about the conversely mentioned suppressive (inhibitory) effect of cytokines that cause inflammation resulting from allergic dermatitis, etc. In other words, the suppressive (inhibitory) effect of cytokines that cause inflammation resulting from allergic dermatitis, etc., and further the anti-inflammatory effect and bactericidal effect are still unknown.

[0015] In view of the above circumstances, the present invention provides an antibacterial agent, an anti-inflammatory agent, and an external skin preparation containing Mucuna bean as an active ingredient. [Means for solving the problem]

[0016] The above object of the antibacterial agent according to the present invention is achieved by containing Mucuna pruriens as an active ingredient.

[0017] Furthermore, the above-mentioned object of the antibacterial agent of the present invention is more effectively achieved by the fact that the Mucuna beans are in the form of a powder, or by the fact that the powder is present at 0.01 to 50% relative to the antibacterial agent, or by the fact that the Mucuna beans are a Mucuna bean extract, or by the fact that the Mucuna bean extract is present in the form of a solution of a diluent at 0.1 to 40% relative to the antibacterial agent.

[0018] Furthermore, the above object of the anti-inflammatory agent according to the present invention can be achieved by containing Mucuna pruriens as an active ingredient.

[0019] Furthermore, the anti-inflammatory agent of the present invention is more effectively achieved when the Mucuna beans are in the form of a powder, or when the powder is at 0.01 to 50% relative to the antibacterial agent, or when the Mucuna beans are a Mucuna bean extract, or when the Mucuna bean extract is a solution of a diluent at 0.1 to 40% relative to the antibacterial agent.

[0020] Furthermore, the above-mentioned object of the external skin preparation according to the present invention is achieved by containing Mucuna pruriens as an active ingredient.

[0021] Furthermore, the skin topical preparation of the present invention is more effectively achieved by the Mucuna bean being in the form of a powder, or by the powder being 0.01 to 50% relative to the antibacterial agent, or by the Mucuna bean being a Mucuna bean extract, or by the Mucuna bean extract being a solution in a diluent at a concentration of 0.1 to 40% relative to the antibacterial agent. Effect of the Invention

[0022] It has been revealed that the antibacterial agent, anti-inflammatory agent, and topical skin preparation of the present invention can reduce production costs by using Mucuna beans, and exhibits a mediator (cytokine) immunosuppressive effect related to allergic dermatitis, as well as an antibacterial effect against Staphylococcus aureus.

[0023] In addition, since Mucuna beans are used, it is possible to prepare antibacterial agents, anti-inflammatory agents, and topical skin agents that have no or few side effects. [Brief description of the drawings]

[0024] [Figure 1] 1 is a graph showing the antibacterial effect of Mucuna extract against resident skin staphylococci in Example 1. [Diagram 2] 1 is a graph showing the effect of Mucuna extract on cytokines produced by human epidermal keratinocytes in Example 2. [Diagram 3] 1 is a graph showing transepidermal water loss in atopic dermatitis model mice in Example 3. [Figure 4] 1 is a graph showing the anti-inflammatory effect when Mucuna extract (Mucuna bean extract) is used in Example 3. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0025] The antibacterial agent, anti-inflammatory agent, and topical skin preparation according to the present invention will be described in detail below. The scientific name of "Mucuna bean (Yasushuu bean or velvet bean)" in the present invention is Mucuna pruriens var. utilis, and it is a plant belonging to the genus Mucuna in the subfamily Fabaceae. In addition, "%" is always by weight unless otherwise specified.

[0026] The antiallergic reaction of the antibacterial agent, anti-inflammatory agent and skin topical preparation according to the present invention is effective against four types of allergic reaction, i.e., types I, II, III and IV, classified by Coombs' classification. Furthermore, among the four types of allergic reaction, it is effective against two types of allergic reaction, i.e., types I and IV, which cause dermatitis. As antibodies against types I and IV of allergic reaction, it is effective (has an inhibitory effect) against mediators such as histamine, ECF-A, leukotriene, PAF, lymphokine, IL (interleukin), IFN-r, cytokines, cytokines, etc., produced by IgE cells and helper T cells.

[0027] Furthermore, the antibacterial agent of the present invention is effective against target bacteria such as staphylococci normally present on the skin, for example, Staphylococcus species such as Staphylococcus aureus, Staphylococcus epidermidis, and saprophytic Staphylococcus, and fungi such as Malassezia, Trichophyton, Aspergillus, and Candida.

[0028] Next, the Mucuna bean in the antibacterial agent, anti-inflammatory agent, and topical skin agent of the present invention will be described.

[0029] First, the case where Mucuna beans are powdered (hereinafter referred to as "powdered Mucuna beans") will be described. Powdered Mucuna beans are one form of an important component that shows effectiveness against mediators such as histamine, ECF-A, leukotriene, PAF, lymphokine, IL (interleukin), IFN-r, cytokines, and cytokines produced by IgE cells and helper T cells in the antibacterial agent, anti-inflammatory agent, and topical skin agent of the present invention. Powdered Mucuna beans are literally powdered Mucuna beans. Incidentally, the powdering can be done by a conventional method (for example, a mill or a freeze-drying method), and any method can be used.

[0030] The amount of powdered Mucuna beans is 0.01% to 80%, preferably 0.1 to 50%, which is more effective for the antibacterial agent, anti-inflammatory agent, and skin topical agent of the present invention. If the amount of mastic powder is less than 0.01%, it will not be effective against mediators such as histamine, ECF-A, leukotriene, PAF, lymphokine, IL (interleukin), IFN-r, cytokine, cytokinin, etc. produced by IgE cells and helper T cells. If the amount of powdered Mucuna beans is more than 80%, there is a concern that some inflammation or allergic reaction will occur, and in some cases, the immunosuppressive effect against mediators such as histamine, ECF-A, leukotriene, PAF, lymphokine, IL (interleukin), IFN-r, cytokine, cytokinin, etc. produced by IgE cells and helper T cells may be lower than within this concentration range. Furthermore, if the amount of powdered Mucuna bean is more than 80%, it may destroy antibodies and other substances necessary for the body.

[0031] Incidentally, in the antibacterial agent, anti-inflammatory agent and topical skin preparation according to the present invention, depending on the form (formulation, etc.) of the antibacterial agent, etc., it may be more convenient to formulate it in a liquid form (including extract or oil form) or gel form rather than in a solid powder form such as powdered Mucuna beans. Here, Mucuna bean extract will be explained. Mucuna bean extract is used by dissolving solid or powdered Mucuna beans in a diluent. The reason for dissolving in a diluent is the result of examining the compatibility with various materials when the antibacterial agent, anti-inflammatory agent and topical skin preparation according to the present invention take various forms such as gel or liquid.

[0032] Diluents for dissolving Mucuna beans include water, ethanol, isopropanol, butanol, glycerin, dipropylene glycol, 1,3-butylene glycol, fatty acid triglyceride (fatty acid derived portion has about 8 to 18 carbon atoms, and preferably has 8 to 12 carbon atoms), tri(caprylic acid / capric acid)glyceride, fatty acid monoglyceride (fatty acid derived portion has about 8 to 18 carbon atoms, and preferably has 8 to 12 carbon atoms), monocapric acid glyceryl, fatty acid ester (fatty acid derived portion has about 8 to 18 carbon atoms, and preferably has 8 to 12 carbon atoms), isopropyl myristate, ethyl isooctanoate, octyldodecyl myristate, Examples of usable fatty acid esters include polyhydric alcohol fatty acid esters such as higher alcohols (about 8 to 22 carbon atoms), oleyl alcohol, sorbitan fatty acid esters (about 8 to 18 carbon atoms in the fatty acid-derived portion, and preferably 8 to 12 carbon atoms), and sucrose fatty acid esters (about 8 to 18 carbon atoms in the fatty acid-derived portion, and preferably 8 to 12 carbon atoms), and / or natural oils and fats, particularly plant-derived unsaturated fatty acids such as olive oil and coconut oil, saturated fatty acids such as palm oil, vegetable or animal oils such as coconut oil, rapeseed oil, cottonseed oil, sunflower oil, perilla oil, linseed oil, fish oil, soybean oil, and corn oil, and alcohol-based solvents (however, ethanol, isopropanol, etc.).

[0033] The concentration of the Mucuna bean extract is preferably 0.1 to 40% in the diluent. If the concentration is less than 0.1%, the immunosuppressive effect on mediators such as histamine, ECF-A, leukotriene, PAF, lymphokine, IL (interleukin), IFN-r, cytokine, cytokinin, etc. produced by IgE cells and helper T cells is reduced or no immunosuppressive effect is obtained, and if the concentration is more than 40%, a heterogeneous solution is formed, and the immunosuppressive effect on the aforementioned mediators is also reduced, although not as much as when the concentration is less than 0.1%.

[0034] The method for preparing the Mucuna bean extract may be a conventional method as long as the above-mentioned concentration is observed. The dissolution temperature of the solid or powdered Mucuna bean may be appropriately increased in consideration of the boiling point of the solvent, and may be room temperature in some cases.

[0035] The antibacterial agent, anti-inflammatory agent, and topical skin preparation of the present invention may take the form of a liquid, gel, pasta (ointment), powder, syrup, tablet, granular powder, capsule, etc. In these dosage forms, the Mucuna bean part may be added during or after production by a known method. The antibacterial agent, anti-inflammatory agent, and topical skin preparation of the present invention may also be applied to either cosmetics and / or transdermal topical preparations.

[0036] As for Mucuna beans, powdered Mucuna beans and Mucuna bean extract may be used in combination.

[0037] The antibacterial agent, anti-inflammatory agent and topical skin preparation according to the present invention can be implemented in the above-mentioned manner, and various additives may be added thereto. The additives will be described below.

[0038] In the antibacterial agent, anti-inflammatory agent and skin external preparation according to the present invention, the above-mentioned components derived from mastic (mastiha) may be used as an auxiliary agent for enhancing the immunosuppressive effect of Mucuna beans (powdered Mucuna beans or Mucuna bean extract). In this specification, "mastic sap" refers to sap taken from Pistacia lentiscus, a member of the Anacardiaceae family, and as described above in the Background Art section, the main components are masticadienoic acid, isomasticadienoic acid, triterpenes, aldehydes, alcohols, poly-β-myrcene, etc. "Mastic resin" refers to mastic sap solidified by natural drying. "Mastic oil" refers to a solution obtained by dissolving mastic sap and / or mastic resin in a diluent described below and filtering the solution. "Mastic essential oil" refers to mastic sap or mastic resin, which is subjected to steam distillation or dry distillation to convert volatile components (mainly terpenes) into essential oil.

[0039] Next, each mastic ingredient will be described.

[0040] First, mastic powder will be described. Mastic powder is one form of an important component that shows effectiveness against mediators such as histamine, ECF-A, leukotriene, PAF, lymphokine, IL (interleukin), IFN-r, cytokine, cytokinin, etc. produced by IgE cells and helper T cells in the antibacterial agent, anti-inflammatory agent, and skin external preparation according to the present invention. As described above, mastic powder is used which is obtained by powdering mastic sap and / or mastic resin. The reason why mastic sap and / or mastic resin are powdered is that the components contained in mastic sap and mastic resin are almost unchanged except for the evaporation of water, and it is sufficient to end up in powder form. Incidentally, the powderization can be performed by a conventional method (for example, a mill or a freeze-drying method, etc.), and any method can be used depending on the state of mastic sap or mastic resin.

[0041] The amount of mastic powder to be blended is 0.01% to 80%, preferably 0.1 to 50%, which is more effective for the antibacterial agent, anti-inflammatory agent, and skin topical agent of the present invention. If the amount of mastic powder blended is less than 0.01%, the effective effect is not shown against mediators such as histamine, ECF-A, leukotriene, PAF, lymphokine, IL (interleukin), IFN-r, cytokine, cytokinin, etc. produced by IgE cells and helper T cells. If the amount of mastic powder blended is more than 80%, there is a concern that some inflammation or allergic reaction may occur, and in some cases, the immunosuppressive effect against mediators such as histamine, ECF-A, leukotriene, PAF, lymphokine, IL (interleukin), IFN-r, cytokine, cytokinin, etc. produced by IgE cells and helper T cells may be lower than within this concentration range. Furthermore, if the amount of mastic powder is more than 80%, it may destroy antibodies and other substances necessary in the body.

[0042] Incidentally, in the antibacterial agent, anti-inflammatory agent and topical skin preparation according to the present invention, depending on the form of the agent, it may be more convenient to incorporate the agent in an oil form, i.e., as mastic oil, rather than incorporating a solid powder such as mastic powder. Here, mastic oil will be explained. As described above, mastic oil is used by dissolving mastic sap (resin) in a diluent. The reason for dissolving it in a diluent is that mastic sap (resin) itself is insoluble in water, and the agent is a result of examining the compatibility with various materials when it takes various forms such as gel or liquid.

[0043] Diluents for dissolving mastic sap (resin) include glycerin, dipropylene glycol, 1,3-butylene glycol, fatty acid triglycerides (the fatty acid-derived portion has about 8 to 18 carbon atoms, and preferably has 8 to 12 carbon atoms), tri(caprylic / capric)glyceride, fatty acid monoglyceride (the fatty acid-derived portion has about 8 to 18 carbon atoms, and preferably has 8 to 12 carbon atoms), glyceryl monocaprate, fatty acid esters (the fatty acid-derived portion has about 8 to 18 carbon atoms, and preferably has 8 to 12 carbon atoms), isopropyl myristate, ethyl isooctanoate, octyldodecyl myristate, higher alcohols ( Examples of usable fatty acid esters include polyhydric alcohol fatty acid esters such as fatty acid esters having about 8 to 22 carbon atoms, oleyl alcohol, sorbitan fatty acid esters (having a fatty acid-derived portion having about 8 to 18 carbon atoms, and preferably having 8 to 12 carbon atoms), and sucrose fatty acid esters (having a fatty acid-derived portion having about 8 to 18 carbon atoms, and preferably having 8 to 12 carbon atoms), and / or natural oils and fats, in particular plant-derived unsaturated fatty acids such as olive oil and coconut oil, saturated fatty acids such as palm oil, vegetable or animal oils such as coconut oil, rapeseed oil, cottonseed oil, sunflower oil, perilla oil, linseed oil, fish oil, soybean oil, and corn oil, and alcohol-based solvents (however, ethanol, isopropanol, etc.).

[0044] The concentration of mastic oil is preferably 0.1 to 60% in the diluent. If the concentration is less than 0.1%, the immunosuppressive effect on mediators such as histamine, ECF-A, leukotriene, PAF, lymphokine, IL (interleukin), IFN-r, cytokine, cytokines, etc. produced by IgE cells and helper T cells is reduced or no immunosuppressive effect is obtained, and if the concentration is more than 60%, it becomes a heterogeneous solution and the immunosuppressive effect on the above-mentioned mediators is also reduced, although not as much as when it is less than 0.1%.

[0045] The mastic oil can be prepared by a conventional method as long as the above concentration is observed. The dissolving temperature of the mastic sap (resin) can be appropriately increased taking into consideration the boiling point of the solvent, and in some cases, it can be at room temperature. It is preferable to use the mastic oil after dissolving the mastic sap (resin) in the diluent mentioned above and filtering it.

[0046] The amount of mastic oil to be blended is 0.01-80%, preferably 0.1-80%, based on the total amount of the antibacterial agent, anti-inflammatory agent and skin topical agent of the present invention, which is more effective. If the amount of mastic oil blended is less than 0.01%, the immunosuppressive effect is not sufficiently exhibited. If the amount of mastic oil blended is more than 80%, there is a concern that some inflammation or allergic reaction may occur, and in some cases, the immunostimulatory effect may be increased more than within this concentration range.

[0047] Next, we will explain mastic essential oil. As mentioned above, mastic essential oil can be obtained by steam distilling mastic sap or resin to extract volatile components (mainly terpenes) and converting them into essential oil. Conventional methods can be used to convert the oil into essential oil.

[0048] The amount of mastic essential oil to be blended is 0.01% to 4%, preferably 0.01% to 3%, based on the total amount of the antibacterial agent, anti-inflammatory agent, and topical skin preparation of the present invention, which is more effective. If the amount of mastic essential oil blended is more than 4%, there is a concern that some kind of inflammation or allergic reaction may occur, as with mastic oil, and in some cases, the inhibitory effect on mediators such as histamine, ECF-A, leukotriene, PAF, lymphokine, IL (interleukin), IFN-r, cytokine, cytokine, etc. produced by IgE cells and helper T cells may decrease. Incidentally, even if mastic essential oil is not included in the antibacterial agent, anti-inflammatory agent, and topical skin preparation of the present invention, i.e., even if it is only mastic powder or mastic oil, it exhibits an inhibitory effect against mediators such as histamine, ECF-A, leukotriene, PAF, lymphokine, IL (interleukin), IFN-r, cytokines, cytokines, etc. produced by IgE cells and helper T cells, but if it is included, an even better inhibitory effect can be obtained.

[0049] Next, we will explain mastic water. As mentioned above, mastic water is made by steam distilling mastic sap or resin to separate volatile components (used for mastic essential oil) and water-soluble components, and the water-soluble components are used.

[0050] The amount of mastic water to be blended is 0.1-100%, preferably 1-50%, based on the total amount of the antibacterial agent, anti-inflammatory agent, and skin topical agent of the present invention, which is more effective. If the amount of mastic water to be blended is less than 0.1%, the immunosuppressive effect will be reduced or will not be exhibited. If the amount of mastic oil to be blended is more than 100%, there is a concern that inflammation or allergic reactions will be caused, and in some cases, the inhibitory effect against these mediators may be reduced compared to within this concentration range, or the immunostimulatory effect may be increased.

[0051] In accordance with the shape and form of the agent described above, the mastic component may be selected from mastic powder, mastic oil, mastic essential oil, and mastic water. Furthermore, two or more of mastic powder, mastic oil, mastic essential oil, and mastic water may be selected.

[0052] In the antibacterial agent, anti-inflammatory agent and topical skin preparation according to the present invention, lactic acid bacteria and lactic acid bacteria production substances can be blended as further auxiliary agents for enhancing the immunosuppressive effect of Mucuna beans (powdered Mucuna beans or Mucuna bean extract). In this case, there is no particular restriction on the body length of the lactic acid bacteria.

[0053] Lactic acid bacteria and bifidobacteria used in the antibacterial agent, anti-inflammatory agent and topical skin preparation for animals according to the present invention include Lactobacillus brevis, Lactobacillus brevis subspecies coagulans, Lactobacillus acidophilus, Lactobacillus gasseri, Lactobacillus mali, Lactobacillus plantarum, Lactobacillus buchneri, Lactobacillus casei, Lactobacillus johnsonii, Lactobacillus gallinarum, Lactobacillus amylovorus, Lactobacillus rhamnosus, Lactobacillus spp. Lactobacillus bacteria such as Lactobacillus rhamnosus, Lactobacillus kefir, Lactobacillus paracasei, Lactobacillus crispatus, Lactobacillus reuteri, Lactobacillus curvatus, Lactobacillus bulgaricus, Lactobacillus fermentum, Lactobacillus helveticus, Lactobacillus sakei, and Lactobacillus salivarius; Lactococcus bacteria such as Lactococcus lactis; Enterococcus faecalis and Enterococcus faecium; Enterococcus bacteria such as Bifidobacterium faecium, Bifidobacterium bifidum, Bifidobacterium longum, Bifidobacterium adolescentis, Bifidobacterium infantis, Bifidobacterium breve, etc.Examples of suitable lactic acid bacteria include Bifidobacterium bacteria such as B. breve, B. catenulatum, and B. animalis lactis. Among these, Lactobacillus bacteria are preferred, and among these, Lactobacillus brevis or L. plantarum are preferred. It is preferable to use killed bacteria for the lactic acid bacteria and bifidobacteria. This is because the preparation of the lactic acid bacteria used in the present invention is easy, and killed bacteria are sufficient to exert the desired immunosuppressive effect. There is no particular restriction on the strain of these bacteria. In addition, lactic acid bacteria production substances that can be used include lactobacillus lysates (e.g., derivatives of Lactobacillus crispatus KT-11, such as product names KT-11HKN and KT-11 HP) and lactic acid bacteria fermentation extracts (e.g., equol lactic acid bacteria, reduced fermenting lactic acid bacteria). Other lactic acid bacteria that can be used include BLIS bacteria (Streptococcus salivarius K12 and M18), Streptococcus thermophilus, Staphylococcus xylosus, Staphylococcus carnosus, Pediococcus pentosaceus, Leuconostoc mesenteroides, and Oenococcus oeni, and either live or killed bacteria can be used.

[0054] In addition, the lactic acid bacteria is preferably blended in the antibacterial agent, anti-inflammatory agent, and skin topical agent of the present invention at 0.01 to 1.0% based on the total amount of the antibacterial agent, anti-inflammatory agent, and skin topical agent. If it is less than 0.01%, it will not exert an immunosuppressive effect. On the other hand, if it is more than 1.0%, it may exert an immunosuppressive effect, but may also exert an immunostimulatory effect.

[0055] Furthermore, by further blending papaya extract and / or chitosan as auxiliary agents similar to the lactic acid bacteria, the antibacterial agent, anti-inflammatory agent and topical skin agent according to the present invention can be obtained.

[0056] Papaya extract is an extract derived from natural papaya fruit, which is extracted by crushing natural papaya fruit and immersing it in a solvent such as ethanol. The papaya fruit may be ripe or green and unripe. The amount of papaya extract is not particularly limited, but it is preferably 0.005% to 10% based on the total amount of the antibacterial agent, anti-inflammatory agent, and skin topical agent of the present invention. If it is less than 0.005%, the above-mentioned effects are not exhibited, and if it is more than 10%, the immunosuppressive effect of the antibacterial agent, anti-inflammatory agent, and skin topical agent of the present invention may be weakened, or the immunoactivating effect may be increased.

[0057] On the other hand, chitosan is obtained by boiling chitin obtained from the exoskeleton of crustaceans such as crabs and shrimps with strong alkali. Since it is a polysaccharide, it is sometimes used as a binder. The amount of chitosan is not particularly limited, but it is preferably 0.005% to 10% based on the total amount of the antibacterial agent, anti-inflammatory agent, and skin topical agent according to the present invention. If it is less than 0.005%, the above-mentioned effects will not be exerted, and if it exceeds 10%, the immunosuppressive effect may be weakened or the immunoactivating effect may be increased.

[0058] Furthermore, chitosan and papaya extract may be added at the same time. In this case, the amount of each is not particularly limited, but it is preferable that the chitosan and papaya extract are each 0.005% to 10%. If the amount is less than 0.005%, the above-mentioned effect is not exerted, and if the amount is more than 10%, the immunosuppressive effect may be weakened.

[0059] Furthermore, in the antibacterial agent, anti-inflammatory agent, and topical skin preparation of the present invention, in addition to chitosan and / or papaya extract, it is possible to blend the following auxiliary agents to enhance the immunosuppressive effect of the mastic components, i.e., to enhance the synergistic effect of the immunosuppressive effect: egg yolk oil, lysine (amino acid), tannin derived from persimmon, polyphenol-containing natural product extract, lactoferrin, fat-soluble vitamins such as vitamin A, vitamin D, vitamin E and / or vitamin K, water-soluble vitamins such as vitamin C and B vitamins including folic acid, coenzymes such as biotin and coenzyme Q10 (ubiquinone), and carotenoids such as lutein, astaxanthin, and beta-carotene. Egg yolk oil will be explained. Egg yolk oil is a mixture of solidified components and fats and oils produced by heating the yolk of a chicken egg, with the fats and oils generally referred to as egg yolk oil or egg oil. Common egg yolk oil contains fat-soluble vitamin vitamin E (tocopherol), egg yolk lecithin, choline (and phosphatidylcholine), phosphatidylamine, fatty acids such as palmitic acid (carbon number 16, unsaturation degree 0), stearic acid (carbon number 18, unsaturation degree 0), oleic acid (carbon number 18, unsaturation degree 1), and linoleic acid (carbon number 18, unsaturation degree 2), phospholipids derived from the fatty acids, triglycerides, etc. Note that although the component ratios of these components may vary somewhat depending on conditions such as the type of chicken, chicken feed, fertilized or unfertilized eggs, or rearing environment, the components themselves do not change regardless of such conditions.

[0060] When egg yolk oil is used in the present invention, there are no particular limitations on the method of producing the egg yolk oil, the difference in the breeding environment of the chickens such as feed and breeding farm, and whether fertilized or unfertilized eggs are used. In addition, in the present invention, either a commercially available product may be used or it may be prepared before use. In addition, in the case of preparation before use, the production method may be a known technique, and there are no particular limitations on the conditions of the production method (for example, heating temperature, material of container, etc.). In addition, in the antibacterial agent, anti-inflammatory agent, and topical skin preparation according to the present invention, egg yolk oil produced from chicken eggs that have been antibody-modified depending on the type of mediator to be inhibited, etc., may be used, but this is not limited, and antibody-modification may not be necessary. Note that antibody-modification of chicken eggs is performed by a conventional method.

[0061] In the present invention, the egg yolk oil is preferably 1 to 30% relative to the antibacterial agent, anti-inflammatory agent, and topical skin preparation of the present invention. If it is less than 1%, the immunosuppressive effect cannot be fully exerted. If it is more than 30%, the immunosuppressive effect is not very strong, or there is a possibility that the mediator related to immunosuppression is activated.

[0062] Next, lysine will be described. When lysine is used in the present invention, it is preferable that the content of lysine is 0.005 to 40% of the antibacterial agent, anti-inflammatory agent, and skin topical agent of the present invention. If the content is less than 0.005%, the immunosuppressive effect cannot be fully exerted. If the content is more than 40%, the immunosuppressive effect may not be very strong, or conversely, an immunostimulatory effect may be exerted. The lysine used in the antibacterial agent, anti-inflammatory agent, and skin topical agent of the present invention may be selected from α-L-lysine, α-L-lysine hydrochloride, or ε-poly(L-lysine).

[0063] Next, when a polyphenol-containing natural product extract is used in the present invention, it is selected from those containing flavonoids, catechins, and tannin-based polyphenols such as indigo extract extract, tea (green tea, oolong tea, black tea) extract, sweet tea extract, matcha powder, cherry leaf extract, lemon extract, grapefruit seed extract, white birch extract, grape, apple, blueberry, raspberry, chocolate, cocoa, soybean, loquat leaf extract, burnet extract, Hypericum extract, witch hazel extract, Scutellaria extract, white birch extract, wild rose extract, perilla seed extract, guava leaf extract, mulberry leaf extract, bay leaf extract, grape seed extract, wine extract, grape leaf extract, apple extract, and apple tannin. In particular, indigo extract extract, tea (green tea) extract, cherry leaf extract, and lemon extract are desirable as those that are expected to have an immunosuppressive effect.

[0064] Incidentally, the polyphenol-containing natural product extract used in the present invention is preferably 0.01 to 40% relative to the antibacterial agent, anti-inflammatory agent, and skin topical agent of the present invention, similar to lysine. If it is less than 0.01%, the immunosuppressive effect cannot be fully exerted. If it is more than 40%, the immunosuppressive effect may not be very pronounced, or conversely, the immunoactivating effect may increase. Note that polyphenol-containing natural product extracts are generally commercially available in the form of a solution of the extract's extraction solvent (e.g., alcohols or water). In this case, since the alcohols or water used as the extraction solvent are not expected to have an antibacterial effect against periodontal disease bacteria, if concentration adjustment is required, the alcohols or water may be used for dilution.

[0065] Next, general additives may be added to the antibacterial agent, anti-inflammatory agent and topical skin preparation of the present invention.

[0066] Examples of inorganic additives include dibasic calcium phosphate dihydrate, dibasic calcium phosphate anhydrate, calcium pyrophosphate, tribasic magnesium phosphate, tribasic calcium phosphate, aluminum hydroxide, light calcium carbonate, heavy calcium carbonate, magnesium carbonate, etc. Among these, one or more of them can be used in combination. The blending amount of these inorganic additives is generally 0.001 to 20% based on the total amount of the antibacterial agent, anti-inflammatory agent, and skin topical agent according to the present invention.

[0067] Examples of humectants include polyhydric alcohols such as glycerin, concentrated glycerin, diglycerin, sorbitol, maltitol, dipropylene glycol, propylene glycol, 1,3-butylene glycol, xylitol, and polyethylene glycol; plant extracts such as rosemary extract, bracken extract, and chrysanthemum flower extract; carbohydrates such as sorbitol liquid; and milk-derived whey; and one or more of these can be used.

[0068] Examples of binders (thickening agents) include alginic acid and its derivatives, such as carrageenans, alginic acid, sodium alginate, propylene glycol alginate, calcium-containing sodium alginate, potassium alginate, calcium alginate, and ammonium alginate; xanthan gum, guar gum, gelatin, agar, sodium carboxymethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, sodium polyacrylate, pullulan; and natural oils and fats, such as coconut oil, palm oil, rapeseed oil, cottonseed oil, sunflower oil, perilla oil, linseed oil, soybean oil, fish oil, and glycerin fatty acid esters. One or more of these can be used in combination.

[0069] Further, preservatives and antiseptics include benzoic acid or sodium benzoate, sorbic acid or potassium sorbate, hinokitiol, grapefruit seed extract, natural fragrance oils such as clove oil and peppermint oil, and essential oils, and one or more of these can be used in combination.

[0070] Examples of pH (hydrogen ion concentration) adjusters include citric acid, (mono- or di-)sodium citrate, malic acid, (mono- or di-)sodium malate, gluconic acid, (mono- or di-)sodium gluconate, succinic acid, sodium succinate, lactic acid, (mono- or di-)sodium lactate, potassium carbonate, sodium bicarbonate, and the like, and one or more of these can be used in combination.

[0071] As a retention agent for retaining (sustaining) the active ingredients of the antibacterial agent, anti-inflammatory agent and topical skin preparation of the present invention, liquid paraffin, gelling hydrocarbons which are mixtures of liquid paraffin and polyethylene, vegetable oils, beeswax, etc. can be used, and these can be used alone or in combination of two or more kinds. The gelling hydrocarbons also function as a gelling agent.

[0072] Sweeteners include sodium saccharin, aspartame, L-phenylalanine compounds, trehalose, stevioside, stevia extract, p-methoxycinnamaldehyde, neohesperidyl dihydrochalcone, perillartine, xylitol, sorbitol, erythritol, honey, oligosaccharides, dextrin, etc. Sugar alcohols such as xylitol, sorbitol, and erythritol also act as immunosuppressant aids.

[0073] As the fragrance component, one or more of 1-menthol, anethole, menthone, cineol, limonene, carvone, methyl salicylate, ethyl butyrate, eugenol, thymol, cinnamaldehyde, trans-2-hexenal, etc. may be used in combination. These components may be blended alone, or essential oils containing them may be used.

[0074] Incidentally, the amount of the additives mentioned above is not particularly limited, but is generally in the range of 0.001 to 20% based on the total amount of the antibacterial agent, anti-inflammatory agent, and topical skin preparation.

[0075] In addition to the above-mentioned fragrance components, fragrance components such as aliphatic alcohols or their esters, terpene hydrocarbons or terpene alcohols, phenol ethers, aldehydes, ketones, lactones, and essential oils (other than mastic essential oil) may be blended within a range that does not impair the effects of the present invention. The blending amount of the above-mentioned fragrances is generally in the range of 0.001 to 20% based on the total amount of the antibacterial agent, anti-inflammatory agent, and topical skin preparation according to the present invention.

[0076] The antibacterial agent, anti-inflammatory agent and skin topical preparation of the present invention may contain other active ingredients in addition to the above. Such active ingredients include ascorbic acid (vitamin C), ascorbate salts, tocopherol, sodium chloride, dextranase, etc., and one or more of these may be contained. The active ingredient is generally in the range of 0.001 to 20% based on the total amount of the antibacterial agent, anti-inflammatory agent and skin topical preparation of the present invention.

[0077] When the above-mentioned mastic resin (as mastic resin liquid), mastic essential oil, egg yolk oil, additives, etc. are mixed with the total amount of the antibacterial agent, anti-inflammatory agent, and topical skin preparation of the present invention within the numerical ranges described above, the remainder may be a solvent (for example, a solvent in which mastic resin has been dissolved), a gelling agent, etc.

[0078] The antibacterial agent, anti-inflammatory agent and topical skin preparation of the present invention can be produced in accordance with a conventional method, and the production method is not particularly limited.

[0079] Although the embodiments of the antibacterial agent, anti-inflammatory agent, and topical skin preparation according to the present invention have been described above, it goes without saying that various embodiments can be adopted without departing from the scope of the claims and the matters described in this specification, without being limited to the above embodiments. EXAMPLES

[0080] The above-mentioned embodiment will be further explained by describing tests (examples) on the antibacterial agent, anti-inflammatory agent, and topical skin preparation according to the present invention.

[0081] [Production Example] How to make Mucuna bean extract In the in vitro experiments described below, an extract extracted with 40% ethanol or an extract mixed with water for injection or culture solution and subjected to ultrasonic treatment was used. Also, a gel containing 1% Mucuna extract was used for the in vivo experiments. Note that the gel (gelling agent) in the gel containing Mucuna extract is not an active ingredient related to antibacterial agents, anti-inflammatory agents, or skin external preparations, so it may be a gel of the diluent described in the above embodiment.

[0082] [Example 1] Bactericidal effect of Mucuna extract against resident skin staphylococci (in vitro experiment) Focusing on the skin-resident staphylococci that are closely related to the progression of inflammatory skin diseases, the bactericidal effect of Mucuna extract in co-culture was investigated. In this Example 1, Staphylococcus pseudintermedius (MRSP), a causative bacterium of superficial pyoderma in dogs and resistant to methicillin, was used. Each staphylococcus was seeded on LB medium (Becton Dickinson and Company) and cultured overnight under aerobic conditions, and then incubated for approximately 10 8 The bacterial solution concentration was adjusted to 100% / ml. Each staphylococcus culture solution was mixed with 40% ethanol or Mucuna extract in a ratio of 100% and 50%, and after leaving it at room temperature for 5 minutes, each reaction solution was smeared on LB agar medium and cultured at 37℃ under aerobic conditions for 24 hours, after which the viable bacterial count was measured.

[0083] The results are shown in Figure 1. In Figure 1, no significant antibacterial effect against Staphylococcus aureus was observed, but it was found that the viable cell count could be suppressed to about one-tenth.

[0084] [Example 2] Effect of Mucuna extract on cytokines produced by human epidermal keratinocytes (in vitro experiment) To investigate the anti-inflammatory effect of Mucuna extract, we investigated the effect of Mucuna extract on inflammatory cytokines (IL-1β, IL-6, IL-8, MCP-1, and TARC) produced by human epidermal keratinocytes (HaCaT cells) when stimulated with IFNγ+TNFα. HaCaT cells were cultured and subcultured in D-MEM medium supplemented with 10% fetal bovine serum. 4 The cells were seeded at 100 cells / well onto a 96-well culture plate and cultured at 37°C under 5% CO2 conditions until the cells became confluent.

[0085] When the Mucuna extract extracted with culture medium was added to the above cells, the survival rate was 70% or less at concentrations higher than 2mg / ml. Therefore, in the experiment to confirm the amount of cytokine production, the maximum concentration was 2mg / ml or less. After seeding the cells with the Mucuna extract, they were stimulated with IFNγ+TNFα, and the amounts of IL-6, IL-8, MCP-1, and TARC produced in the culture medium 24 hours after culture were measured by ELISA.

[0086] The results are shown in Figure 2. As shown in Figure 2, the amount of inflammatory cytokines (IL-6, IL-8, TARC, MCP-1) produced by human epidermal keratinocytes was significantly reduced by treatment with Mucuna extract, suggesting the anti-inflammatory effect of Mucuna beans.

[0087] [Example 3] Confirmation of the anti-inflammatory effect of Mucuna-containing gel on atopic dermatitis model mice (in vivo experiment) To investigate the efficacy of Mucuna-containing gel against atopic dermatitis, a study was conducted using a mouse model of Th2-type hapten-induced atopic dermatitis. Seven-week-old female NC / Nga mice were used to prepare atopic dermatitis model mice. Atopic dermatitis symptoms were induced by repeatedly administering 2,4-toluene diisocyanate, which induces Th2 immune responses, percutaneously to the shaved back and ear skin at least 24 hours before administration, dissolved in acetone at a concentration of 5% or 0.5%. After atopic dermatitis symptoms were sufficiently induced, the animals were divided into a placebo group and a Mucuna gel administration group based on the atopic dermatitis score, and percutaneous administration of placebo gel or Mucuna-containing gel was performed daily during the period. During the experiment, atopic dermatitis symptoms (symptoms were rated from mild to severe on a scale of 0-6), transepidermal water loss (TEWL), dorsal skin thickness, auricular skin thickness, skin pH, and itch behavior were analyzed every week. On the day after the final measurement, blood was collected from the posterior vena cava under isoflurane inhalation anesthesia, and auricular lymph nodes and auricular and dorsal skin samples were taken. Lymph nodes collected at the time of dissection were crushed on a 70 μm cell strainer using RPMI-1640 medium. The total cell count of the obtained cell suspension was measured, and the proportion of immune-competent cells was analyzed using a flow cytometer.

[0088] In Example 3, FIG. 3 shows the transepidermal water loss of atopic dermatitis model mice, and FIG. 4 shows the anti-inflammatory effect when a gel containing Mucuna extract (Mucuna bean extract) was used.

[0089] As shown in Figures 3 and 4, the effect of Mucuna-containing gel on atopic dermatitis symptoms was investigated using a hapten-induced mouse model. A tendency for improvement in atopic dermatitis symptoms and transepidermal water loss was observed in the Mucuna extract gel group compared to the placebo group, but no statistically significant changes were observed between the two groups.

[0090] On the other hand, analysis of tissues collected from animals showed an overall tendency for improvement with administration of Mucuna extract gel. In particular, IL-4 and TSLP expression in the skin was significantly reduced in the Mucuna extract gel group. Meanwhile, the number of effector helper T cells and IgE-positive B cells in the auricular lymph nodes was significantly reduced in the Mucuna-containing gel group. Furthermore, the amount of TARC produced by T cells was also significantly reduced in the Mucuna-containing gel group.

[0091] [Statistical tests in Examples 1 to 3] For each test item in Examples 1 to 3, the presence or absence of statistically significant differences between the control group and each bentonite-administered group was analyzed at the risk level of 5 and 1%. For data between the vehicle control group and the test substance group, Bartlett's test for equal variance was first performed. If this test determined that the variances in all dose groups were uniform (p>0.05), the presence or absence of significant differences between the groups was examined using one-way analysis of variance. If a significant difference was observed between the groups as a result (p≦0.05), Dunnett's multiple comparison test was performed to determine the presence or absence of significant differences between the control group and each administration group. If the Bartlett's test for equal variance determined that the variances of each group were not equal (p≦0.05), the presence or absence of significant differences between the groups was examined using the Kruskal-Wallis test. As a result, the presence or absence of significant differences between the control group and each administration group was examined using a Dunnett-type nonparametric multiple comparison test.

[0092] [Considerations in Examples 1 to 3] In Examples 1 to 3, for the purpose of investigating the effect of Mucuna extract on atopic dermatitis symptoms, 1) the antibacterial effect of Mucuna extract against Staphylococcus aureus (Example 1), 2) the efficacy of Mucuna extract on cytokines produced by keratinocytes (Example 2), and 3) the anti-inflammatory effect of Mucuna-containing gel in a hapten-induced mouse model (Example 3) were investigated.

[0093] While no efficacy was observed against Staphylococcus aureus, which is an exacerbating factor of skin allergy diseases, the cytokines (IL-6, IL-8, MCP-1, TARC) produced by keratinocytes stimulated with IFNγ and TNFα were significantly suppressed by exposure to Mucuna extract. In addition, the number of cells and the number of cells on the skin barrier were significantly reduced by percutaneous administration of Mucuna-containing gel to atopic dermatitis model mice, and although the effect of cells produced was minor, the number of effector helper T cells and B cells in the lymph nodes were significantly reduced, and TARC production produced by T cells was also significantly reduced by administration of Mucuna-containing gel, suggesting that Mucuna extract may directly act on local skin immunity and help control inflammation.

[0094] The production of inflammatory cytokines was also significantly reduced by administration of the Mucuna-containing gel, suggesting that Mucuna extract may act directly on local skin immunity and help control inflammation. [Industrial Applicability]

[0095] In the above-mentioned embodiments and examples, reference has been made to the antibacterial agent, anti-inflammatory agent, and topical skin agent of the present invention, but since the present invention uses Mucuna beans, it can be used as an anti-allergic drug for humans or dogs, cats, etc.

Claims

1. An antibacterial agent characterized by containing Mucuna pruriens as an active ingredient.

2. The antibacterial agent according to claim 1 , wherein the Mucuna pruriens is in the form of a powder.

3. The antibacterial agent according to claim 2, wherein the powder is present in an amount of 0.01 to 50% based on the antibacterial agent.

4. The antibacterial agent according to claim 1 , wherein the Mucuna bean is a Mucuna bean extract.

5. The antibacterial agent according to claim 4, wherein the Mucuna bean extract is a solution of 0.1 to 40% diluent relative to the antibacterial agent.

6. An anti-inflammatory agent characterized by containing Mucuna pruriens as an active ingredient.

7. The anti-inflammatory agent according to claim 6, wherein the Mucuna beans are in the form of a powder.

8. The anti-inflammatory agent according to claim 7, wherein the powder is present at a concentration of 0.01 to 50% based on the anti-inflammatory agent.

9. The anti-inflammatory agent according to claim 6, wherein the Mucuna bean is Mucuna bean extract.

10. The anti-inflammatory agent according to claim 9, wherein the Mucuna bean extract is a solution of 0.1 to 40% diluent relative to the anti-inflammatory agent.

11. A skin topical preparation characterized by containing Mucuna pruriens as an active ingredient.

12. The skin topical preparation according to claim 11 , wherein the Mucuna pruriens is in the form of a powder.

13. The external preparation for skin according to claim 12, wherein the powder is present in an amount of 0.01 to 50% based on the amount of the external preparation for skin.

14. The topical skin preparation according to claim 11, wherein the Mucuna bean is a Mucuna bean extract.

15. The topical skin preparation according to claim 11, wherein the Mucuna bean extract is a solution of 0.1 to 40% diluent relative to the topical skin preparation.

Citation Information

Patent Citations

  • Method for preparing extract having immunofunction-enhancing activity and apoptosis-inducing function to cancer cell and imparting anticancer or cancer-preventing effect from leguminosae plant, the extract, health food material containing the extract, health food and health drink water containing the health food material

    JP2008081478A

  • Immunoregulatory composition containing cirsium maritimum makino extract

    JP2018083764A

  • Anti-allergy functional food composition, cosmetic, and transdermal topical drug

    WO2021235512A1